Enhancing the efficacy of mesenchymal stem cell therapy.
Mesenchymal stem cell (MSC) therapy is entering a challenging phase after completion of many preclinical and clinical trials. Among the major hurdles encountered in MSC therapy are inconsistent stem cell potency, poor cell engraftment and survival, and age/disease-related host tissue impairment. The recognition that MSCs primarily mediate therapeutic benefits through paracrine mechanisms independent of cell differentiation provides a promising framework for enhancing stem cell potency and therapeutic benefits. Several MSC priming approaches are highlighted, which will likely allow us to harness the full potential of adult stem cells for their future routine clinical use.
Michalis Mastri, Huey Lin, Techung Lee, Department of Biochemistry, University at Buffalo, Buffalo, NY 14214, United States.
Michalis
M
Mastri
Michalis Mastri, Huey Lin, Techung Lee, Department of Biochemistry, University at Buffalo, Buffalo, NY 14214, United States.
Huey
H
Lin
Michalis Mastri, Huey Lin, Techung Lee, Department of Biochemistry, University at Buffalo, Buffalo, NY 14214, United States.
Techung
T
Lee
Clinical trial; Mesenchymal stem cell; Paracrine; Therapy